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Abstract
© 2015, Springer Science+Business Media New York.  Lung cancer is  the leading cause of
cancer-related deaths worldwide. The initiation and progression of lung cancer is the result of
the  interaction  between  permanent  genetic  and  dynamic  epigenetic  alterations.  DNA
methylation is the best studied epigenetic mark in human cancers. Altered DNA methylation in
cancer was identified in 1983. Within 30 years of this discovery, DNA methylation inhibitors are
used clinically to treat a variety of cancers, highlighting the importance of the epigenetic basis
of cancer. In addition, histone modifications, nucleosome remodeling, and micro RNA (miRNA)-
mediated gene regulation are also fundamental to tumor genesis. Distinct chromatin alterations
occur in all stages of lung cancer, including initiation, growth, and metastasis. Therefore, stage-
specific epigenetic changes can be used as powerful and reliable tools for early diagnosis of
lung cancer and to monitor patient prognosis. Moreover, since epigenetic changes are dynamic
and reversible, chromatin modifiers are promising targets for the development of more effective
therapeutic strategies against cancer. This review summarizes the chromatin alterations in lung
cancer,  focusing  on  the  diagnostic  and  therapeutic  approaches  targeting  epigenetic
modifications  that  could  help  to  reduce  the  high  case-fatality  rate  of  this  dreadful  disease.
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